Opinion
Video
Author(s):
Panelists discuss key findings from the KEYNOTE-A18 trial, which evaluated pembrolizumab in combination with chemoradiotherapy for high-risk locally advanced cervical cancer, highlighting the implications for treatment approaches in this patient population.
Video content above is prompted by the following:
Experts Highlight Noteworthy Research From the 2024 ESMO Congress
MR-Linac Radiotherapy Limits Target Volume, Brain Tissue Exposure in High-Grade Glioma
PFS Data for 177Lu-Dotatate Surpass Clinical Benchmarks in Refractory Meningioma
Nivolumab Plus Radiotherapy Reduces Rates of Biochemical Recurrence in Gleason Grade 5 Prostate Cancer
2 Commerce Drive
Cranbury, NJ 08512